Concept paper on the quality and safety aspects of RNA interference and RNA antisense oligonucleotide therapies as veterinary medicinal products
Guideline on data requirements for changes to the strain composition of authorised equine influenza vaccines in line with WOAH recommendations - Revision 1
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2026
Human medicines European public assessment report (EPAR): Azacitidine Adienne, azacitidine, Status: Application withdrawn
Human medicines European public assessment report (EPAR): Cavoley, pegfilgrastim, Status: Opinion
Human medicines European public assessment report (EPAR): Evlarco, obicetrapib,ezetimibe, Status: Opinion
Human medicines European public assessment report (EPAR): Icotyde, icotrokinra hydrochloride, Status: Opinion
Human medicines European public assessment report (EPAR): Lynavoy, Linerixibat, Status: Opinion
Human medicines European public assessment report (EPAR): Lyrokaul, lerodalcibep, Status: Opinion
Human medicines European public assessment report (EPAR): Meplyffa, arimoclomol, Status: Opinion